试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-08-18
Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression.
编号:NCT00408967登记状态:入组前撤回企业 / 申办者:EMD Serono
药物 / 成分:Tucotuzumab celmoleukin (EMD 273066)
登记的停止原因(原文):Th trial got cancelled and no subjects signed informed consent form (ICF); study design not appropriate any longer.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-08-18
EBMtrialcentral- Comparing Initial Diuretic Therapies Using a Collaborative Network
编号:NCT01748123登记状态:入组前撤回企业 / 申办者:Johns Hopkins University
药物 / 成分:Chlorthalidone、Hydrochlorothiazide
登记的停止原因(原文):Slow enrollment
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-08-17
Alipogene Tiparvovec for the Treatment of LPLD Patients
编号:NCT02904772登记状态:入组前撤回企业 / 申办者:UniQure Biopharma B.V.
药物 / 成分:alipogene tiparvovec、Prednisolone、Cyclosporins、Mycophenolate mofetil
登记的停止原因(原文):uniQure, has decided not to renew the Marketing Authorization of Glybera in the EU. This decision is not related to any safety, efficacy or quality issue
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-08-16
A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Metastatic Bone Disease.
编号:NCT00478270登记状态:入组前撤回企业 / 申办者:Hoffmann-La Roche
药物 / 成分:ibandronate [Bondronat]
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-08-16
The Use of Tranexamic Acid (TXA) Intravenously, to Reduce Blood Loss in Proximal Femur Surgery
编号:NCT02164565登记状态:入组前撤回企业 / 申办者:HaEmek Medical Center, Israel
药物 / 成分:Tranexamic Acid (TXA) treatment、control grup: without Tranexamic Acid (TXA) treatment.
登记的停止原因(原文):Enrollment difficulties
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-08-16
Ketorolac for Analgesia followiNG Autologous Breast RecOnstructiOn
编号:NCT03007381登记状态:入组前撤回企业 / 申办者:Nova Scotia Health Authority
药物 / 成分:Ketorolac Tromethamine、Normal Saline
登记的停止原因(原文):No funding.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-08-14
Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia (FTD)
编号:NCT00127114登记状态:入组前撤回企业 / 申办者:Johns Hopkins University
药物 / 成分:Amantadine、Placebo
登记的停止原因(原文):No funding and exclusion criteria were to stringent.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-08-10
Autologous Adipose Tissue Stromal Vascular Fraction Cells for Rheumatoid Arthritis
编号:NCT01885819登记状态:入组前撤回企业 / 申办者:Translational Biosciences
药物 / 成分:Autologous stromal vascular fraction cells
登记的停止原因(原文):per sponsor decision
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-08-10
Safety and Feasibility Study of Autologous Stromal Vascular Fraction (SVF) Cells for Treatment of Osteoarthritis
编号:NCT01885832登记状态:入组前撤回企业 / 申办者:Translational Biosciences
药物 / 成分:Autologous adipose tissue stromal vascular fraction
登记的停止原因(原文):per sponsor decision
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2017-08-10
Safety and Feasibility Study of Mesenchymal Trophic Factor (MTF) for Treatment of Osteoarthritis
编号:NCT02003131登记状态:入组前撤回企业 / 申办者:Translational Biosciences
药物 / 成分:Trophic factors from umbilical cord mesenchymal stem cells
登记的停止原因(原文):No enrollment
查看官方原始记录 ↗